Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures ...

Indian pharmaceutical companies are intensifying their push into the rapidly expanding US oncology generics market, now valued at $145 billion and growing at 11% annually, a new report reveals.

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

A team of US researchers has found a new drug delivery system that showed more efficacy and improved the treatment of a rare ...

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that has spread to ...

A breakthrough in cancer treatment has emerged from a multi-institutional study led by the Moffitt Cancer Center in Florida, ...

April 15, 2025 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...